A New Biodegradable Nanoprobe for More Accurate Cancer Detection

With young Turkish scientists among its members, a group of researchers from Imperial College London has worked with second harmonic generation (second harmonic generation – SHG) — a new type of bright technology that emits light — on new Imperial-patented nanoprobes called bioharmonophores, which it has developed.
This new biodegradable nanoprobe can illuminate tumors brightly and precisely. Tested in zebrafish, the new nanoprobes could help identify the location, shape, and size of cancer more accurately, and could aid diagnosis and treatment in the future.
A new biocompatible technology for cancer detection
Most nanoprobes are fluorescent; they absorb light of a particular color, such as blue, and then emit light of a different color, such as green. However, because tissues in the human body can also emit light, distinguishing nanoprobe light from background light can be difficult and may lead to misinterpretation.
Researchers at Imperial College London have used a new type of bright technology that emits light, known as second harmonic generation (second harmonic generation – SHG), to develop Imperial-patented bioharmonophores , a new type of nanoprobe.
ACS Nano published the study, whose first author, Ali Yasin Sonay, earned his bachelor's and master's degrees in Biotechnology at Yeditepe University. He completed his doctorate in Zurich, Switzerland, working on self-assembling biodegradable nanoparticles for deep-tissue optical imaging modalities. In 2018, he joined Memorial Sloan Kettering Cancer Center in Dr. Grimm's laboratory to develop smart photoacoustic cancer imaging agents.
In this study, Sine Yağanoğlu, and Ayşen Ünsal, two other young Turkish scientists, also participated.
After testing the nanoprobes in zebrafish embryos, the researchers found that bioharmonophores designed to target cancer cells marked tumors more brightly than fluorescent nanoprobes. Their light can easily be detected and distinguished by the tissues that generally emit light. They also attach precisely to tumor cells rather than healthy cells, making them more sensitive in detecting the tumor threshold.
The research is being led by Dr. Periklis Pantazis in Imperial's Department of Bioengineering. Dr. Periklis Pantazis says about their research: “Bioharmonophores could be a more effective way of detecting tumors than the methods currently available. They uniquely combine features that could be excellent for cancer diagnosis and treatment in clinical practice, and with further research could ultimately improve patient outcomes.”
Bioharmonophores are both biocompatible and biodegradable because they are made from peptides, the same components as the proteins found in the body. They are naturally metabolized in the body within 48 hours and therefore cannot pose long-term health risks.
Details of the study
- For precise tumor detection, the researchers first injected cancer cells into zebrafish embryos, allowing the tumor cells to multiply uncontrollably.
- After 24 hours, they infected the bioharmonophores designed to target p32 peptide molecules specifically found in tumor cells.
- They then used light microscopy imaging to examine how the engineered bioharmonophores detected tumors and found that they had exceptional detection sensitivity. This means that they attached to specific tumor cells rather than healthy cells.

(a) Only cancer cells can be specifically targeted in vivo with bioharmonophores.
(b) A composite image of the cancer model in a 5 dpf zebrafish embryo (left). A close-up of one of the tumor regions (right) reveals DsRed-labeled tumors (magenta) adjacent to eGFP-labeled vasculature (green).
(c) Red rectangles labeled C1−4 indicate the regions of interest shown in more detail. It shows images of labeled cancer cells, with details of bioharmonophores (white) labeling down to a single cancer cell (magenta) in solid tumors (c1−4).
How do bioharmonophores differ from other methods?
Fluorescence-activated nanoprobes tend to attach less specifically, meaning that they may incorrectly identify healthy cells as tumor cells or vice versa.
The researchers also found that, unlike fluorescence, bioharmonophores did not “bleach” over time. This means that they did not lose their ability to emit light over time. In addition, the light emitted by bioharmonophores did not saturate as it did with fluorescent nanoprobes. In other words, they became brighter when illuminated with more light. This made the tumors even clearer.
Dr. Pantazis: “It is very important for tumor nanoprobes to mark cells specifically and clearly for cancer diagnosis. Our study shows that very bright bioharmonophores could be a powerful tool for cancer diagnosis and targeting treatments in the coming years.” he said.
- Related topic: How is cancer diagnosed?
Bioharmonophores are inexpensive to produce, reproducible, and scalable, and last about 2 days at room temperature. They now need testing in mammals to determine how well the findings translate beyond zebrafish.
The use of bioharmonophores in cancer treatment
The researchers are also examining how bioharmonophores could guide surgical procedures during cancer surgery and how they could produce light at different frequencies to have the potential to kill tumor cells with high precision.
Sources
2. Imperial College London. (2021, March 11). Tumors illuminated brightly and precisely with new biodegradable nanoprobe. ScienceDaily. Retrieved March 13, 2021 from www.sciencedaily.com/releases/2021/03/210311142113.htm
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.